Prospective high-throughput genome profiling of advanced cancers: results of the PERMED-01 clinical trial

Prospective high-throughput genome profiling of advanced cancers: results of the PERMED-01 clinical trial

Abstract Background The benefit of precision medicine based on relatively limited gene sets and often-archived samples remains unproven. PERMED-01 (NCT02342158) was a prospective monocentric clinical trial assessing, in adults with advanced solid cancer, the feasibility and impact of extensive molec...

Full description

Bibliographic Details
Main Authors: François Bertucci, Anthony Gonçalves, Arnaud Guille, José Adelaïde, Séverine Garnier, Nadine Carbuccia, Emilien Billon, Pascal Finetti, Patrick Sfumato, Audrey Monneur, Christophe Pécheux, Martin Khran, Serge Brunelle, Lenaïg Mescam, Jeanne Thomassin-Piana, Flora Poizat, Emmanuelle Charafe-Jauffret, Olivier Turrini, Eric Lambaudie, Magali Provansal, Jean-Marc Extra, Anne Madroszyk, Marine Gilabert, Renaud Sabatier, Cécile Vicier, Emilie Mamessier, Christian Chabannon, Jihane Pakradouni, Patrice Viens, Fabrice André, Gwenaelle Gravis, Cornel Popovici, Daniel Birnbaum, Max Chaffanet
Format: Article
Language:English
Published: BMC 2021-05-01
Series:Genome Medicine
Subjects:
aCGH
Advanced cancers
Mutation
PERMED-01 trial
Precision medicine
Sequencing
Online Access:https://doi.org/10.1186/s13073-021-00897-9

Internet

https://doi.org/10.1186/s13073-021-00897-9

Similar Items